OLDAKOWSKI MARK 4

What Happened

• Mark Oldakowski, Chief Operating Officer of Bionano Genomics (BNGO), received a grant of 27,737 derivative shares reported as $0.00 on Feb 2, 2026. The filing lists this as an award/derivative (transaction code A) rather than a cash purchase or sale.

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-04 (timely filing).
• Transaction type/code: Award/Grant (A) of derivative securities; reported acquisition price: $0.00; reported dollar value: $0.
• Vesting: Per footnote, the option award vests monthly over 48 months beginning one month after the vesting commencement date, becoming fully vested and exercisable after four years.
• Shares owned after transaction: Not specified in the filing.
• No 10b5-1 plan, tax-withholding sale, or immediate exercise/sale was reported.

Context

• This was a compensation award (derivative/option-style grant), not a market purchase or sale. Such grants are commonly used to retain and incentivize executives and do not represent an immediate cash investment or realization of proceeds. Because the award vests over four years, the shares are not fully exercisable or freely tradable until vesting occurs.